ARTA
PTCT icon

A.R.T. Advisors’s PTC Therapeutics PTCT Stock Holding History

A.R.T. Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-29,556
Closed -$1.39M – 1586
2018
Q3 		$1.39M Sell
29,556
-124,400
-81% -$5.15M 0.06% 439
2018
Q2 		$5.19M Buy
153,956
+11,000
+8% +$343K 0.21% 106
2018
Q1 		$3.87M Sell
142,956
-907
-0.6% -$23K 0.16% 163
2017
Q4 		$2.4M Buy
143,863
+98,800
+219% +$1.67M 0.11% 308
2017
Q3 		$901K Buy
+45,063
New +$882K 0.05% 582
2017
Q2 		– Sell
-88,889
Closed -$874K – 1660
2017
Q1 		$874K Sell
88,889
-36,811
-29% -$446K 0.04% 608
2016
Q4 		$1.37M Buy
+125,700
New +$1.32M 0.08% 387
2016
Q3 		– Sell
-149,159
Closed -$1.05M – 1060
2016
Q2 		$1.05M Sell
149,159
-70,229
-32% -$515K 0.05% 530
2016
Q1 		$1.41M Buy
+219,388
New +$3.81M 0.06% 446
2014
Q4 		– Sell
-24,570
Closed -$1.08M – 1601
2014
Q3 		$1.08M Buy
+24,570
New +$769K 0.05% 482

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

A.R.T. Advisors's PTCT Position: Q4 2018 in Review

A.R.T. Advisors sold out of PTC Therapeutics (PTCT) in Q4 2018, closing a stake of 29,556 shares — an estimated $1.39M sold.

A.R.T. Advisors first reported a position in PTCT in Q3 2014 and held it in 10 quarters. The position peaked at $5.19M in Q2 2018. 164 funds tracked by Wall St. Rank hold PTCT as of Q4 2018.

  • A.R.T. Advisors reported no remaining PTC Therapeutics position as of Q4 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 29,556 PTC Therapeutics shares in Q4 2018, an estimated $1.39M.
  • A.R.T. Advisors first reported a position in PTC Therapeutics in Q3 2014 and held it in 10 quarters.
  • A.R.T. Advisors's PTC Therapeutics position peaked at $5.19M in Q2 2018.
  • 164 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.